DAX24.117 +1,0%Est505.583 +1,0%MSCI World4.308 ±0,0%Top 10 Crypto16,13 +1,8%Nas22.647 -0,1%Bitcoin99.931 +2,9%Euro1,1751 +0,1%Öl65,36 -2,5%Gold3.871 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Wolfspeed A41JEH Lufthansa 823212 Siemens Energy ENER6Y HENSOLDT HAG000 Novo Nordisk A3EU6F Tesla A1CX3T Alibaba A117ME Deutsche Telekom 555750 Amazon 906866 Bayer BAY001 BYD A0M4W9
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Shutdown: DAX stark - über 24.000 Punkten -- US-Börsen schwächeln -- VW mit zahlreichen Entlassungen in 2025 -- AES, DroneShield, Wolfspeed, Gold, Rheinmetall, RENK, HENSOLDT im Fokus
Top News
Nike-Aktie trotzt erwarteter höherer Belastung durch Trump-Zölle - Umbau hilft Nike-Aktie trotzt erwarteter höherer Belastung durch Trump-Zölle - Umbau hilft
Imperial Brands-Aktie in Rot: Reemtsma-Werk in Langenhagen droht Aus Imperial Brands-Aktie in Rot: Reemtsma-Werk in Langenhagen droht Aus
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Jazz Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
111,75 EUR -0,15 EUR -0,13 %
FSE
135,04 USD +3,30 USD +2,50 %
BTT
Jazz Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.6,65 Mrd. EUR

KGV14,24Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JS1K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B4Q5ZN47

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Societ...
PR NewswireJazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR NewswireJazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
PR NewswireJazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract...
PR NewswireJazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PR NewswireJazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic H...
PR NewswireJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PR NewswireJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PR NewswirePharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenan...
PR NewswireJazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance...
PR NewswireJazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
PR NewswireJazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
PR NewswireJazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
PR NewswireJazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies
PR NewswireJazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
PR NewswireJazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
PR NewswireJazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
PR NewswireJazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
PR NewswireJazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
PR NewswireJazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
PR NewswireJazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
PR NewswireJazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
PR NewswireJazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
PR NewswireJazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
PR NewswireJazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
PR NewswireJazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
PR NewswireJazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.